Experimental strategies to improve drug-target identification in mass spectrometry-based thermal stability assays
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Mass spectrometry (MS)-based thermal stability assays have recently emerged as one of the most promising solutions for the identification of protein-ligand interactions. Here, we have investigated eight combinations of several recently introduced MS-based advancements, including the Phase-Constrained Spectral Deconvolution Method, Field Asymmetric Ion Mobility Spectrometry, and the implementation of a carrier sample as improved MS-based acquisition approaches for thermal stability assays (iMAATSA). We used intact Jurkat cells treated with a commercially available MEK inhibitor, followed by heat treatment, to prepare a set of unfractionated isobarically-labeled proof-of-concept samples to compare the performance of eight different iMAATSAs. Finally, the best-performing iMAATSA was compared to a conventional approach and evaluated in a fractionation experiment. Improvements of up to 82% and 86% were demonstrated in protein identifications and high-quality melting curves, respectively, over the conventional approach in the proof-of-concept study, while an approximately 12% improvement in melting curve comparisons was achieved in the fractionation experiment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As a result, many drug candidates fail during late-stage clinical trials (phase II trials), leading to resource wastage and underscoring the urgent need for innovative strategies to enhance drug development (6).”
From DORSSAA: Drug-Target interactOmics Resource Based on Stability/Solubility Alteration Assay (2026) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344
Tracking cancer drugs in living cells by thermal profiling of the proteome
Savitski, M. M., Reinhard, F. B. M., Franken, H., Werner, T., Savitski, M. F., Eberhard, D., Molina, D. M., Jafari, R., Dovega, R. B., Klaeger, S., et al. (2014) · Science · doi:10.1126/science.1255784 · Cited by 1,187
Budnik, B., Levy, E., Harmange, G., & Slavov, N. (2018) · Genome Biology · doi:10.1186/s13059-018-1547-5 · Cited by 832
Single-cell proteomic and transcriptomic analysis of macrophage heterogeneity using SCoPE2
Specht, H., Emmott, E., Petelski, A. A., Huffman, R. G., Perlman, D. H., Serra, M., Kharchenko, P., Koller, A., & Slavov, N. (2021) · Genome Biology · doi:10.1186/s13059-021-02267-5 · Cited by 493
Schweppe, D. K., Prasad, S., Belford, M. W., Navarrete-Perea, J., Bailey, D. J., Huguet, R., Jedrychowski, M. P., Rad, R., McAlister, G., Abbatiello, S. E., et al. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.8b05399 · Cited by 229
Kurzawa, N., Becher, I., Sridharan, S., Franken, H., Mateus, A., Anders, S., Bantscheff, M., Huber, W., & Savitski, M. M. (2020) · Nature Communications · doi:10.1038/s41467-020-19529-8 · Cited by 53
Research works printed but not linked: 28
- Seashore-Ludlow, B., Axelsson, H. & Lundbäck, T. Perspective on CETSA literature: toward more quantitative data interpretation. SLAS Discov.: Adv. Sci. Drug Discov. 25, 118–126 (2020). · DOI · Paper page
- Morgan, P. et al. Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nat. Rev. Drug Discov. 17, 167–181 (2018). · DOI · Paper page
- Bunnage, M. E. Getting pharmaceutical R&D back on target. Nat. Chem. Biol. 7, 335–339 (2011). · DOI · Paper page
- Friman, T., Chernobrovkin, A., Martinez Molina, D. & Arnold, L. CETSA MS profiling for a comparative assessment of FDA-approved antivirals repurposed for COVID-19 therapy identifies TRIP13 as a remdesivir off-target. SLAS Discovery: Adv. Life Sci. R. D. 26, 336–344 (2021). · DOI
- Molina, D. M. et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341, 84 (2013). · DOI · Paper page
- Grinfeld, D., Aizikov, K., Kreutzmann, A., Damoc, E. & Makarov, A. Phase-constrained spectrum deconvolution for fourier transform mass spectrometry. Anal. Chem. 89, 1202–1211 (2017). · DOI
- Kelstrup, C. D. et al. Limits for resolving isobaric tandem mass tag reporter ions using phase-constrained spectrum deconvolution. J. Proteome Res. 17, 4008–4016 (2018). · DOI · Paper page
- Gregus, M., Kostas, J. C., Ray, S., Abbatiello, S. E. & Ivanov, A. R. Improved sensitivity of ultralow flow LC-MS-based proteomic profiling of limited samples using monolithic capillary columns and FAIMS technology. Anal. Chem. 92, 14702–14712 (2020). · DOI
- Li, J., Van Vranken, J. G., Paulo, J. A., Huttlin, E. L. & Gygi, S. P. Selection of heating temperatures improves the sensitivity of the proteome integral solubility alteration assay. J. Proteome Res. 19, 2159–2166 (2020). · DOI · Paper page
- Yi, L. et al. Boosting to amplify signal with isobaric labeling (BASIL) strategy for comprehensive quantitative phosphoproteomic characterization of small populations of cells. Anal. Chem. 91, 5794–5801 (2019). · DOI · Paper page
- Peck Justice, S. A. et al. Boosting detection of low-abundance proteins in thermal proteome profiling experiments by addition of an isobaric trigger channel to TMT multiplexes. Anal. Chem. 93, 7000–7010 (2021). · DOI
- Sridharan, S. et al. Proteome-wide solubility and thermal stability profiling reveals distinct regulatory roles for ATP. Nat. Commun. 10, 1155 (2019). · DOI · Paper page
- Isshiki, Y. et al. Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent. Bioorg. Med. Chem. Lett. 21, 1795–1801 (2011). · DOI
- Franken, H. et al. Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry. Nat. Protoc. 10, 1567–1593 (2015). · DOI · Paper page
- Ishii, T. et al. CETSA quantitatively verifies in vivo target engagement of novel RIPK1 inhibitors in various biospecimens. Sci. Rep. 7, 1–14 (2017). · DOI · Paper page
- Martinez Molina, D. & Nordlund, P. The cellular thermal shift assay: a novel biophysical assay for in situ drug target engagement and mechanistic biomarker studies. Annu. Rev. Pharmacol. Toxicol. 56, 141–161 (2016). · DOI · Paper page
- Reinhard, F. B. et al. Thermal proteome profiling monitors ligand interactions with cellular membrane proteins. Nat. Methods 12, 1129–1131 (2015). · DOI · Paper page
- Jarzab, A. et al. Meltome atlas—thermal proteome stability across the tree of life. Nat. Methods 17, 495–503 (2020). · DOI · Paper page
- Cheung, T. K. et al. Defining the carrier proteome limit for single-cell proteomics. Nat. Methods 18, 76–83 (2021). · DOI · Paper page
- Swearingen, K. E. et al. Nanospray FAIMS fractionation provides significant increases in proteome coverage of unfractionated complex protein digests. Mol. Cell Proteom. 11, M111 014985 (2012). · DOI
- Ohren, J. F. et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat. Struct. Mol. Biol. 11, 1192–1197 (2004). · DOI · Paper page
- Herneisen, A. L. et al. Identifying the target of an antiparasitic compound in toxoplasma using thermal proteome profiling. ACS Chem. Biol. 15, 1801–1807 (2020). · DOI
- Kawatkar, A. et al. CETSA beyond soluble targets: a broad application to multipass transmembrane proteins. ACS Chem. Biol. 14, 1913–1920 (2019). · DOI
- Hughes, C. S. et al. Ultrasensitive proteome analysis using paramagnetic bead technology. Mol. Syst. Biol. 10, 757 (2014). · DOI · Paper page
- Stopfer, L. E., Conage-Pough, J. E. & White, F. M. Quantitative consequences of protein carriers in immunopeptidomics and tyrosine phosphorylation MS(2) analyses. Mol. Cell Proteom. 20, 100104 (2021). · DOI
- Klann, K., Tascher, G. & Münch, C. J. M. C. Functional translatome proteomics reveal converging and dose-dependent regulation by mTORC1 and eIF2α. 77, 913–925.e914 (2020). · DOI · Paper page
- Lange, O., Damoc, E., Wieghaus, A. & Makarov, A. J. I. J. O. M. S. Reprint of “Enhanced Fourier transform for Orbitrap mass spectrometry”. 377, 338–344 (2015). · DOI
- Perez-Riverol, Y. et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res. 47, D442–D450 (2019). · DOI · Paper page
Cited by
DORSSAA: Drug-Target interactOmics Resource Based on Stability/Solubility Alteration Assay
Zangene, E., Gholizadeh, E., Schwämmle, V., Saei, A. A., Wilhelm, M., Käll, L., & Jafari, M. (2026) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2026.101603 · Cited by 3
Metadata
- Authors
- Phaneuf, C. G., Aizikov, K., Grinfeld, D., Kreutzmann, A., Mourad, D., Lange, O., Dai, D., Zhang, B., Belenky, A., Makarov, A. A., & Ivanov, A. R.
- Venue
- Communications Chemistry
- Published
- 2023-04-06
- Volume
- 6
- Issue
- 1
- ISSN
- 2399-3669
- Cited by
- 15
- References
- 6
- Language
- en
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Funders
- U.S. Department of Health & Human Services | NIH | Center for Information Technology (R01CA218500, R35GM136421)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Experimental strategies to improve drug-target identification in mass spectrometry-based thermal stability assays. https://app.cochat.ai/papers/10.1038/s42004-023-00861-1
- The paper
- Phaneuf, C. G., Aizikov, K., Grinfeld, D., Kreutzmann, A., Mourad, D., Lange, O., Dai, D., Zhang, B., Belenky, A., Makarov, A. A., & Ivanov, A. R. (2023). Experimental strategies to improve drug-target identification in mass spectrometry-based thermal stability assays. Communications Chemistry. https://doi.org/10.1038/s42004-023-00861-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.